Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis

Immunological Reviews

Volumn 164, Issue , 1998, Pages 157-168

  Vincent, Angela ^a   Willcox, Nick ^a   Hill, Marguerite ^a   Curnow, John ^a   MacLennan, Cal ^a   Beeson, David ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN SUBUNIT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CELL CLONE; CONTROLLED STUDY; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; THYMOMA; THYMUS HYPERPLASIA;

ANIMALS; EPITOPES; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; THYMUS GLAND;

EID: 0031785532     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01217.x     Document Type: Article

References (87)

1. Compston DAS, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-1810.
3. Willcox N, Vincent A. Myasthenia gravis as an example of organ-specific autoimmune disease. In: Bird G, Calvert JE, eds. B lymphocytes in human disease. Oxford: Oxford University Press; 1988. p. 469-506.
4. Willcox N. Myasthenia gravis. Curr Opin Immunol 1993;5:910-917.
5. Vincent A. Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 1994;4:355-371.
6. Lindstrom J. Shelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1988;42:233-284.
7. Vincent A. Experimental autoimmune myasthenia gravis. In: Cohen IR, Miller A, eds. Autoimmune disease models: a guidebook. New York: Academic Press Inc; 1994. p. 83-106.
8. Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the α subunit. Proc Natl Acad Sci USA 1988;85:2899-2903.
9. Lindstrom JM, Einarson BL, Lennon VA, Seybold ME. Pathological mechanisms in experimental autoimmune myasthenia gravis, 1. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976;144:726-738.
10. Jermy A, Beeson D, Vincent A. Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice. Eur J Immunol 1993;23:973-976.
11. Fujii Y, Lindstrom J. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis: response to subunits and synthetic peptides. J Immunol 1988;140:1830-1837.
12. Shenoy M, Golusko E, Christadoss P. The pathogenic role of acetylcholine receptor a chain epitope within a 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin Immunol Immunopathol 1994;73: 338-343.
13. Oshima M, Pachner AR, Atassi MZ. Profile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and nonsusceptible mouse strains after different periods of immunization with the receptor. Mol Immunol 1994;31:833-843.
14. Fujii Y, Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. J Immunol 1988;141:3361-3369.
15. Yeh T-M, Krolick KA. T cells reactive with a small synthetic peptide of the acetylcholine receptor can provide help for a clonotypically heterogeneous antibody response and subsequently impaired muscle function. J Immunol 1990;144:1654-1660.
16. Rosenberg JS, Oshima M, Atassi MZ. B cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol 1996;157:3192-3199.
17. 4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains. J Autoimmunol 1992;5:27-46.
18. Wu B, Deng C, Goluszko E, Christadoss P. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J Immunol 1997;159:3016-3023.
19. + cells sensitized to nicotinic acetylcholine receptor. J Immunol 1994;147:1484-1491.
20. bm12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. Scand J Immunol 1995;42:215-225.
21. Zhang G-X, Ma C-G, Xiao B-G, Bakhiet M, Link H, Olsson T. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995;25:1191-1198.
22. Zhang G-X, et al. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 1996;184:349-356.
23. Shenoy M, Kaul R, Goluszko E, David C, Christados P. Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. J Immunol 1994;153:5330-5335.
24. Tzartos S, Remoundos MS. Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor a subunit. Dissecting a potentially myasthenogenic epitope. Eur J Biochem 1992;207:915-922.
25. Palace J, Vincent A, Beeson D, Newsom-Davis J. Immunogenicity of human recombinant acetylcholine receptor α subunit: cytoplasmic epitopes dominate the antibody response in four mouse strains. Autoimmunity 1994;18:113-119.
26. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor a 138-199: determinant spreading initiates autoimmunity to self antigen in rabbits. Immunol Lett 1994;39:269-275.
27. Lennon VA, Lambert EH, Leiby KR, Okarma TB, Talib S. Recombinant human acetylcholine receptor-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991;146:2245-2248.
28. Sano M, McCormick DJ, Talib S, Griesmann GE, Lennon VA. Identification of three extended antibody-binding segments in recombinant human muscle acetylcholine receptor α subunit extracellular domain 1-210. Int Immunol 1991;3:983-989.
29. Yoshikawa H, Lambert EH, Walser-Kuntz DR, Yasukawa Y, McCormick DJ, Lennon VA. A 17-mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. J Immunol 1997;159:1570-1577.
30. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-208.
31. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. 1. Patients with generalised myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982;49:257-265.
32. Tzartos SJ, et al. The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis. Autoimmunity 1991;8:257-270.
33. Loutrari H, Kokla A, Trakas N, Tzartos SJ. Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis. Clin Exp Immunol 1997;109:538-546.
34. Whiting PJ, Vincent A, Newsom-Davis J. Myasthenia gravis: monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment. Neurology 1986;36:612-617.
35. Vincent A, et al. Antibody heterogeneity and specificity in myasthenia gravis. Ann N Y Acad Sci 1987;505:326-332.
36. Heidenreich F, Vincent A, Willcox N, Newsom-Davis J. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 1988;38:1784-1788.
37. Graus YF, et al. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997;158:1919-1929.
38. Farrar J, et al. Diverse Fabs specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. Int Immunol 1997;9:1311-1318.
39. Protti P, Manfredi AA, Horton RM, Bellone M, Conti-Tronconi EM. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today 1993;14:363-368.
40. Wang Z-Y, Okita DK, Howard J, Conti-Fine BM. Th1 epitope repertoire on the α subunit of human muscle acetylcholine receptor in myasthenia gravis. Neurology 1997;48:1643-1653.
41. Melms AS, et al. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989;83:785-790
42. 86 HLA-DRβ dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci USA 1991;88:7343-7347.
43. Harcourt G, et al. Detection of alpha subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient. Proc R Soc Lond B Biol Sci 1993;254:1-6.
44. Nagvekar N, et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitzation of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998;101:2268-2277.
45. Hawke S, Willcox N, Harcourt G, Vincent A, Newsom Davis J. Stimulation of human T cells by sparse antigens captured on immunomagnetic particles. J Immunol Methods 1992;155:41-48.
46. + T cell clone from a myasthenia gravis patient. J Neuroimmunol 1993;46;57-66.
47. Matsuo H, et al. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol 1995;155:3683-3692.
48. Hawke S, Matsuo H, Nicholle M, Malcherek G. Melms A, Willcox N. Autoimmune T cells in myasthenia gravis heterogeneity and potential for specific immunotargeting. Immunol Today 1993;17:307-311.
49. Beeson D, Amar M, Bermudez I, Vincent A, Newsom-Davis J. Stable high level expression of the adult subtype of human muscle acetylcholine receptor in the TE671 cell line following transfection with cDNA encoding the e subunit. Neurosci Lett 1996;207:57-60.
50. Beeson D, Jacobson L, Newsom-Davis J, Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996;47:1552-1555.
51. MacLennan C, Beeson D, Buijs A-M, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997;41:423-431.
52. Riemersma S, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98:2358-2363.
53. Thomas JA, Willcox N, Newsom-Davis J. Immunohistological studies of the thymus in myasthenia gravis. Correlation with clinical state and thymocyte culture responses. J Neuroimmunol 1982;3:319-335.
54. Guigou V, Emilie D, Berrih Aknin S, Fumoux F, Fougereau M, Schiff C. Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin Exp Immunol 1991;83:262-266.
55. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990;28:312-319.
56. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981;31:935-943.
57. Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 1983;33:1276-1282.
58. Fujii Y, Hashimoto J, Monden Y, Ito T, Nakahara K, Kawashima Y. Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis. J Immunol 1986;136:887-891.
59. Fujii Y, Monden Y, Makahara K, Hashimoto J, Kawashima Y. Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus and thymoma. Neurology 1984;34:1182-1186.
60. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1987;12;212-222.
61. Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Adv Neuroimmunol 1994;4:373-386.
62. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kammsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996;157:3752-3760.
63. Gilhus NI, et al. Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. J Neuroimmunol 1995;56:65-76.
64. Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the endplate in 30 patients. Neurology 1993;43:1167-1172.
65. Michaelis D, Goebels N, Hohlfeld R. Consitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol 1993;143:1142-1149.
66. Hohlfeld R, Engel A. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 1990;136:503-508.
67. Curnow SJ, Willcox N, Vincent A. Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFN-γ secretion and cytotoxicity. J Neuroimmunol 1998;86:53-62.
68. Willcox HNA. Thymic tumours with myasthenia gravis or bone marrow dyscrasias. In: Peckham M, ed. Oxford textbook of oncology. Oxford: Oxford University Press; 1995. p. 1562-1568.
69. Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 1987;127:447-460.
70. Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82:284-288.
71. Mygland A, Tysnes O-B, Matre R, Volpe P, Aarli JA. Gilhus N-E. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32:589-591.
72. Mygland A et al. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62:79-83.
73. Gautel M, et al. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993;43:1581-1585.
74. Mohan S, Babohn RJ, Krolick KA. Unexpected cross-reactivity between myosin and a main immunogenic region (MIR) of the acetylcholine receptor by antisera obtained from myasthenia gravis patients. Clin Immunol Immunopathol 1992;64:218-226.
75. Osborn M, Marx A, Kirchner T, Tzartos SJ, Plessman W, Weber K. A shared epitope in the acetylcholine receptor-a subunit and fast troponin I of skeletal muscle. Am J Pathol 1992;140:1215-1223.
76. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992;662:331-336.
77. Marx A, et al. Proteins with epitopes of the acetylcholine receptor in epithelial cell cultures of thymomas in myasthenia gravis. Am J Pathol 1989;134:865-877.
78. Marx A, et al. Expression of neurofilaments and of a titin epitope in thymic epidielial tumours. Am J Pathol 1996;148:1839-1850.
79. Nagvekar N, Jacobson LW, Willcox N, Vincent A. Expitopes expressed in myasthenia gravis thymomas are not recognized by patients' T cells or autoantibodies. Clin Exp Immunol 1998;112:17-20.
80. Hara Y, et al. Neoplastic epithelial cells express α-subunit of muscle nicotinic acetylcholine receptor in thymomas from patients with myasthenia gravis. FEBS Lett 1991;279:137-140.
81. Wheatley LM, et al. Molecular evidence for the expression of nicotinic acetylcholine receptor α-chain in mouse thymus. J Immunol 1992;148:3105-3109.
82. Meager A, Willcox N, Vincent A, Newsom-Davis J. Spontaneous neutralising antibodies to interferon-α and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997;350:1596-1597.
83. Balasa B, et al. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997;186:385-391.
84. Moiola L, et al. IL-12 is required for the induction of experimental myasthenia gravis, an antibody-mediated disease. Eur J Immunol (In press).
85. Gu D, et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma at the neuromuscular junction. J Exp Med 1995;181:547-557.
86. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor α subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;840:1174-1180.
87. Vincent A, Willcox N, Roxanis I, Newsom-Davis J, MacLennan C, Beeson D. Thymoma and autoimmune neurological disorders. In: Marx A, Muller-Hemmelink H-K, eds. Epithelial tumors of the thymus. New York: Plenum Press: 1997. p. 195-204.